CHICAGO /PRNewsSpreader/ -- Shamital Corp. announced today that the Food and Drug Administration has granted approval of BilgonX™. This first-of-its-kind technology is being hailed as a breakthrough in the Marketing and PR Industry.

Brenda Verbosae, Vice President and Head of Oncology at Shamital said, " BilgonX™ offers great hope to thousands of agencies, clients and their families. We look forward to a similar outcome in a number of other countries, where regulatory reviews are presently underway. It is our hope to make this important new treatment available to patients suffering from the devastating consequences of invoiceitis."

BilgonX™ is a non-selective beta blocker mainly used in the treatment of hypertension. Originally developed to treat hemorrhoids and diverticulitis, its effect on the hormone adrenaline has made it popular among actors dealing with severe stage fright. Now scientists are now using it in their research on memory. In recent years researchers have discovered that certain drugs can interrupt the memory process and frustrate the “consolidation” of a traumatic event. Researchers found that not only does the drug address the symptoms of post traumatic stress, if applied directly it can specifically help clients manage everything from regular monthly heavy-flow bleeding to huge unexplainable billing spikes.

Shamital Corp. is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top drug companies in the world with healthcare sales of over $17 gazillion and leading positions in sales of gastrointestinal, oncology, anaesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products.

To prevent automated Bots from commentspamming, please enter the string you see in the image below in the appropriate input box. Your comment will only be submitted if the strings match. Please ensure that your browser supports and accepts cookies, or your comment cannot be verified correctly.Enter the string from the spam-prevention image above:

Remember Information? Subscribe to this entry

Submitted comments will be subject to moderation before being displayed.